ArticlesSingle-agent bevacizumab or Lomustine (cas 13010-47-4) versus a combination of bevacizumab plus Lomustine (cas 13010-47-4) in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial
-
Add time:09/04/2019 Source:sciencedirect.com
SummaryBackgroundTreatment options for recurrent glioblastoma are scarce, with second-line chemotherapy showing only modest activity against the tumour. Despite the absence of well controlled trials, bevacizumab is widely used in the treatment of recurrent glioblastoma. Nonetheless, whether the high response rates reported after treatment with this drug translate into an overall survival benefit remains unclear. We report the results of the first randomised controlled phase 2 trial of bevacizumab in recurrent glioblastoma.
We also recommend Trading Suppliers and Manufacturers of Lomustine (cas 13010-47-4). Pls Click Website Link as below: cas 13010-47-4 suppliers
Prev:Short communicationA stability-indicating liquid chromatographic method for Lomustine (cas 13010-47-4)
Next:The methylation of arsenate by a marine alga Polyphysa Peniculus in the presence of L-METHIONINE-METHYL-D3 (cas 13010-53-2)) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Short communicationA stability-indicating liquid chromatographic method for Lomustine (cas 13010-47-4)09/03/2019
- ArticlesLomustine (cas 13010-47-4)-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial09/02/2019
- Original ArticleCombination toceranib and Lomustine (cas 13010-47-4) shows frequent high grade toxicities when used for treatment of non-resectable or recurrent mast cell tumours in dogs: A European multicentre study09/01/2019
- Spectroscopic analysis of the interaction of Lomustine (cas 13010-47-4) with calf thymus DNA08/31/2019
- ArticlesRegorafenib compared with Lomustine (cas 13010-47-4) in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial08/30/2019
- Lomustine (cas 13010-47-4)08/29/2019
- Electrochemical behaviour of anticancer drug Lomustine (cas 13010-47-4) and in situ evaluation of its interaction with DNA08/28/2019